| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NCHEMBIO.1952 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nchembio.1952 |
| P932 | PMC publication ID | 4677459 |
| P698 | PubMed publication ID | 26502155 |
| P50 | author | Paul Czodrowski | Q56112063 |
| Rahul S Samant | Q56488780 | ||
| Elizabeth Fraser | Q57324094 | ||
| Florence Raynaud | Q62089079 | ||
| Felix Rohdich | Q28039044 | ||
| Paul A Clarke | Q38546651 | ||
| Trevor Dale | Q47354747 | ||
| P2093 | author name string | Dirk Wienke | |
| Alexis de Haven Brandon | |||
| Daniel Schwarz | |||
| Gary Box | |||
| Julian Blagg | |||
| Melanie Valenti | |||
| Suzanne A Eccles | |||
| Christina Esdar | |||
| Paul Workman | |||
| Klaus Schneider | |||
| Mark Stubbs | |||
| Aurélie Mallinger | |||
| Richard Schneider | |||
| Djordje Musil | |||
| Kai Schiemann | |||
| Oliver Poeschke | |||
| Sharon Gowan | |||
| Andree Blaukat | |||
| Maria-Jesus Ortiz-Ruiz | |||
| Olajumoke Adeniji-Popoola | |||
| Ken Ewan | |||
| Robert TePoele | |||
| Will Court | |||
| Dennis Waalboer | |||
| P2860 | cites work | Mediator is a transducer of Wnt/beta-catenin signaling. | Q52569557 |
| Target cells for the cytotoxic effects of carcinogens in the murine small bowel | Q53491958 | ||
| Proteomics strategy for quantitative protein interaction profiling in cell extracts. | Q54721073 | ||
| HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia | Q24294721 | ||
| Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling | Q24316697 | ||
| Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways | Q24317164 | ||
| The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder | Q24318515 | ||
| A transposon-based genetic screen in mice identifies genes altered in colorectal cancer | Q24655169 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| The Mediator complex: a central integrator of transcription | Q26849595 | ||
| Structure-kinetic relationship study of CDK8/CycC specific compounds | Q27677859 | ||
| Wnt/beta-catenin signaling in development and disease | Q27860784 | ||
| Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. | Q28116486 | ||
| Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II | Q28284175 | ||
| CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response | Q28284234 | ||
| CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity | Q28294122 | ||
| The two faces of Cdk8, a positive/negative regulator of transcription | Q28300466 | ||
| The multitalented Mediator complex | Q28582418 | ||
| Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration | Q28587140 | ||
| Proximal events in Wnt signal transduction | Q29616162 | ||
| How were new medicines discovered? | Q29616641 | ||
| Guidelines for the welfare and use of animals in cancer research | Q33903753 | ||
| Probing the probes: fitness factors for small molecule tools | Q34001269 | ||
| CDK8 is a positive regulator of transcriptional elongation within the serum response network | Q34094495 | ||
| The art of the chemical probe | Q34098693 | ||
| The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers | Q34119756 | ||
| Target validation using chemical probes | Q34333826 | ||
| Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. | Q34355711 | ||
| Involvement of Mediator complex in malignancy. | Q34392169 | ||
| The roles of mediator complex in cardiovascular diseases | Q34416269 | ||
| CDK8: a positive regulator of transcription | Q34558375 | ||
| CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. | Q34561921 | ||
| Regulation of the oxidative stress response through Slt2p-dependent destruction of cyclin C in Saccharomyces cerevisiae | Q34588127 | ||
| The why and how of phenotypic small-molecule screens | Q34626953 | ||
| Primary Bioassay of Human Tumor Stem Cells | Q34661809 | ||
| The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. | Q34676833 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8 | Q34828705 | ||
| Function and regulation of the Mediator complex | Q34904976 | ||
| Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. | Q35560868 | ||
| Can we safely target the WNT pathway? | Q35591995 | ||
| ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia | Q35751114 | ||
| In vivo and in vitro models for the therapeutic targeting of Wnt signaling using a Tet-OΔN89β-catenin system | Q36075534 | ||
| Identifying the proteins to which small-molecule probes and drugs bind in cells | Q37114227 | ||
| Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. | Q37395251 | ||
| Non-ATP competitive protein kinase inhibitors. | Q37768464 | ||
| Chemoproteomic approaches to drug target identification and drug profiling. | Q37963212 | ||
| Chemical biology approaches to target validation in cancer | Q38245047 | ||
| Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors | Q38281465 | ||
| CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. | Q39394499 | ||
| Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5. | Q39401156 | ||
| Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models | Q39413387 | ||
| Integrated genome-wide analysis of transcription factor occupancy, RNA polymerase II binding and steady-state RNA levels identify differentially regulated functional gene classes | Q39474443 | ||
| Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. | Q39785181 | ||
| Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis | Q43234873 | ||
| Roles of cyclin-dependent kinase 8 and β-catenin in the oncogenesis and progression of gastric adenocarcinoma | Q43507637 | ||
| HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature | Q44780029 | ||
| P433 | issue | 12 | |
| P921 | main subject | CCT251545 | Q27075796 |
| P304 | page(s) | 973-980 | |
| P577 | publication date | 2015-10-26 | |
| P1433 | published in | Nature Chemical Biology | Q904026 |
| P1476 | title | A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease | |
| P478 | volume | 11 |
| Q42695709 | 2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19. |
| Q33804888 | A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response. |
| Q28817622 | Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases |
| Q47129821 | CDK8 Kinase Activity Promotes Glycolysis. |
| Q52345436 | CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells. |
| Q33906319 | Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology |
| Q64229834 | Cyclin C: The Story of a Non-Cycling Cyclin |
| Q92578496 | De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder |
| Q42141778 | Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. |
| Q38785642 | Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells |
| Q27703668 | Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19 |
| Q100316302 | Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 Mediator kinases |
| Q39125016 | Inhibitors of cyclin-dependent kinases as cancer therapeutics |
| Q52319726 | Interferon Independent Non-Canonical STAT Activation and Virus Induced Inflammation. |
| Q52653219 | Kinase inhibitors: the road ahead. |
| Q98282864 | Manipulating the mediator complex to induce naïve pluripotency |
| Q55509442 | Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). |
| Q30846907 | Polypharmacology in Precision Oncology: Current Applications and Future Prospects |
| Q96127369 | Quantifying CDK inhibitor selectivity in live cells |
| Q54977199 | Recent advances in the development of indazole based anti-cancer agents. |
| Q90750142 | Regulatory functions of the Mediator kinases CDK8 and CDK19 |
| Q33779684 | SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains |
| Q89554723 | Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance |
| Q91143046 | Small-molecule targeting of brachyury transcription factor addiction in chordoma |
| Q58762403 | Structural insights into the functional diversity of the CDK-cyclin family |
| Q47423882 | Structure-based discovery of cyclin-dependent protein kinase inhibitors. |
| Q47423892 | Structure-based drug design: aiming for a perfect fit. |
| Q41596446 | The complex structure and function of Mediator |
| Q55034077 | Transcriptional kinases: Less is more (or less). |
| Q28078703 | Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials |
Search more.